King's College London

Research portal

Improving the economics of NASH/NAFLD treatment through the use of systems biology

Research output: Contribution to journalReview articlepeer-review

Jim Bosley, Christofer Boren, Sunjae Lee, Morten Grotli, Jens Nielsen, Mathias Uhlen, Jan Boren, Adil Mardinoglu

Original languageEnglish
Pages (from-to)1532-1538
JournalDRUG DISCOVERY TODAY
Volume22
Issue number10
Early online date20 Jul 2017
DOIs
E-pub ahead of print20 Jul 2017
PublishedOct 2017

King's Authors

Abstract

Nonalcoholic steatohepatitis (NASH) is a severe form of nonalcoholic fatty liver disease (NAFLD). We surveyed NASH therapies currently in development, and found a significant variety of targets and approaches. Evaluation and clinical testing of these targets is an expensive and time-consuming process. Systems biology approaches could enable the quantitative evaluation of the likely efficacy and safety of different targets. This motivated our review of recent systems biology studies that focus on the identification of targets and development of effective treatments for NASH. We discuss the potential broader use of genome-scale metabolic models and integrated networks in the validation of drug targets, which could facilitate more productive and efficient drug development decisions for the treatment of NASH.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454